The Next Frontier for GLP 1s: A Promising yet Elusive Path Recent research has shed new light on the potential of GLP 1 medications to combat inflammation and tissue damage.
A study published in Cell Metabolism found that semaglutide, a type of GLP 1 medication, shows promise in alleviating osteoarthritis related inflammation and cartilage destruction – effects that are independent of weight loss.
This research has significant implications for the estimated 530 million people worldwide who live with osteoarthritis.